UPLOAD Filing
Q/C TECHNOLOGIES, INC.
Date: Sept. 18, 2025 · CIK: 0001321834 · Accession: 0000000000-25-010162
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36268
Letter
Re: TNF Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-36268 Dear Mitchell Glass:
September 18, 2025
Mitchell Glass President and Chief Medical Officer TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Rick Werner, Esq
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 18, 2025 Mitchell Glass President and Chief Medical Officer TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 Re: TNF Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-36268 Dear Mitchell Glass: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rick Werner, Esq </TEXT> </DOCUMENT>